financetom
Business
financetom
/
Business
/
Alibaba develops next-gen chip for agentic AI, Chinese media says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alibaba develops next-gen chip for agentic AI, Chinese media says
Mar 23, 2026 8:54 PM

BEIJING, March 24 (Reuters) - Alibaba ( BABA ) on

Tuesday revealed its next-generation XuanTie C950 5-nanometer

processor at an internal conference on Tuesday, local media

reported, as the Chinese tech giant gears up for the shift

towards agentic AI.

* The 3.2 GHz server chip, built using open-source RISC-V

chip architecture, was billed as "the highest performing RISC-V

CPU in the world" at a conference hosted by DAMO Academy,

Alibaba's ( BABA ) research arm, according to the reports.

* The chip performs more than three times faster than its

predecessor, the XuanTie C920, the reports said.

* The company did not reveal which fab manufactured the

chip.

* Alibaba ( BABA ) did not immediately respond to an emailed request

for comment.

* Alibaba ( BABA ) is accelerating in-house chip development through

its T-Head semiconductor arm, primarily focusing on the Zhenwu

810E chip series for AI training and inference, while the

XuanTie series is focused on high-performance cloud systems and

agentic AI.

* The move comes after Alibaba ( BABA ) last week launched Wukong,

its enterprise platform optimised for AI agent workflows, as

companies and institutions throughout China adopt OpenClaw.

* Its international equivalent, Accio Work, was launched on

Monday. The agentic AI platform says it can autonomously run

complex business operations for small and medium-sized

enterprises.

* The firm reorganised some of its AI-focused teams under

the newly created Alibaba Token Hub earlier this month, which

focuses on building AI work platforms for enterprises.

* The business strategy shift comes as Alibaba ( BABA ) finds new

ways to ensure profitability as Chinese AI models' token prices

have dropped dramatically amid fierce domestic competition.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Nov 7, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle...
Strategy Prices IPO of Euro-Denominated Perpetual Preferred Shares
Strategy Prices IPO of Euro-Denominated Perpetual Preferred Shares
Nov 7, 2025
08:34 AM EST, 11/07/2025 (MT Newswires) -- Strategy (MSTR) said Friday it priced an initial public offering a day earlier of about 7.8 million shares of 10% series A perpetual preferred stock at 80 euros ($92.48) each. The issuance and sale of the stock under the ticker STRE is scheduled to settle on Nov. 13, the company said. Strategy said...
Boralex Q3 Loss Widens on Weak Power Prices Despite Higher Output
Boralex Q3 Loss Widens on Weak Power Prices Despite Higher Output
Nov 7, 2025
08:34 AM EST, 11/07/2025 (MT Newswires) -- Boralex ( BRLXF ) on Friday said its third-quarter loss widened as revenue fell as weaker prices offset higher power production. The renewable-power company said it lost $27 million, or $0.26 per share, compared to a loss of $14 million, or $0.13, in the year-prior quarter. The result lagged the FactSet consensus estimate...
Gilead Sciences Says Long-Term Data Supports Sustained Efficacy, Safety of Primary Biliary Cholangitis Drug
Gilead Sciences Says Long-Term Data Supports Sustained Efficacy, Safety of Primary Biliary Cholangitis Drug
Nov 7, 2025
08:34 AM EST, 11/07/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday that new long-term data on its drug Livdelzi showed consistent efficacy and safety in treating primary biliary cholangitis, including in patients who switched from obeticholic acid, with sustained improvements in liver stiffness over three years. The company said the long-term study showed that 67% of participants...
Copyright 2023-2026 - www.financetom.com All Rights Reserved